Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Chase Pharmaceuticals
1825 K Street, NW Suite 520
Washington, DC 20006
Phone: 202-223 -7002
http://chasepharmaceuticals.com/

Chase is an early stage drug development company, based in Washington, DC. Its mission is to improve the quality of life for those suffering from disorders of brain function, especially cognitive dysfunction of the Alzheimer's type. In the service of this goal, Chase Pharmaceuticals seeks to advance the development of its own intellectual property towards commercial products that satisfy crucial unmet medical needs. Current efforts, focused on pharmaceuticals for Alzheimer type dementia, include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The privately held company received Series A funding in 2010 and 2011 from Brain Trust Accelerator Fund in support of its program of Phase I clinical trials.

Key Contact
Name
John M. Siebert
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
05/12/14 $21,000,000 Series B Brain Trust Accelerator Fund
Cipla Ventures
Edmond de Rothschild Investment Partners
New Rhein Healthcare Investors
undisclosed